Cargando…

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

AIM: Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rognoni, Carla, Falivena, Camilla, Costa, Francesco, Armeni, Patrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883339/ https://www.ncbi.nlm.nih.gov/pubmed/36662417 http://dx.doi.org/10.1007/s40273-022-01220-z

Ejemplares similares

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
por: Degerlund Maldi, Kinza, et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis
por: Borsoi, Ludovica, et al.
Publicado: (2022)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case
por: Tarantola, Alice, et al.
Publicado: (2023)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
por: Salahudeen, Mohammed S, et al.
Publicado: (2020)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
por: Liu, Peng, et al.
Publicado: (2022)

The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2021)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
por: Veraart, J.K.E., et al.
Publicado: (2023)

The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study
por: Armeni, Patrizio, et al.
Publicado: (2015)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2019)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
por: Del Sant, Lorena Catarina, et al.
Publicado: (2022)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
por: Rognoni, Carla, et al.
Publicado: (2023)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2020)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis
por: Borsoi, Ludovica, et al.
Publicado: (2023)

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
por: Correia-Melo, Fernanda S., et al.
Publicado: (2018)

The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy
por: Perrone, Valentina, et al.
Publicado: (2021)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021)

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
por: Breeksema, Joost J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7f1cr22beb1hb5ml6q9cguhd2